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The biological determinants of the phenotypic variation in sporadic
Creutzfeldt-Jakob disease (sCJD) are unknown. To categorize sCJD
cases, the prion protein (PrP) codon 129 genotype and the bio-
chemical characteristics of the disease-associated form of PrP (PrPSc)
canbe combined to form six subgroups (MM1,MM2,MV1,MV2, VV1,
and VV2). This classiﬁcation largely correlates with the known vari-
ation in the clinical and pathological features of sCJD, with the MM1
and MV1 cases representing the “classic” phenotype of sCJD. To ad-
dress how this classiﬁcation relates to different strains of sCJD we
have inoculated each subgroup of sCJD to a panel ofmice expressing
different forms of the human PRNP gene (129MM, 129VV, and
129MV). We have established that all subtypes are transmissible to
at least one genotype of mouse, and both agent and host factors
determine transmission efﬁciency and the form of PrPSc deposited
in the brain. Moreover, we have identiﬁed four distinct strains of
sCJD using our in vivo strain typing panel.
codon 129 genotype | mouse model | prion disease | transmission strains
Transmissible spongiform encephalopathies (TSE) or priondiseases are a group of fatal neurodegenerative diseases that
include Creutzfeldt-Jakob disease (CJD) in humans, scrapie in
sheep and goats, bovine spongiform encephalopathy (BSE) in
cattle, and chronic wasting disease in deer and elk. These dis-
eases can be sporadic, familial, or acquired by infection, and the
common hallmark is a distinct pathology in the central nervous
system characterized by neuronal loss, spongiform degeneration,
and gliosis (1). Sporadic CJD (sCJD) is the idiopathic form of
CJD. There is much that remains to be understood about how
and why this disease occurs and the speciﬁc biochemical and
cellular pathogenesis that leads to the neurodegenerative phe-
notype. Most frequently, sCJD is a rapidly progressive dementia
that occurs between 50 and 75 y of age and has a short clinical
duration of weeks to a few months (2).
Expression of the host-encoded cellular prion protein (PrPC) is
essential for an individual to be susceptible to disease, because
PrP null mice are refractory to TSE infection (3). PrPC is a gly-
coprotein with two consensus sites for attachment of N-linked
glycans, which are variably occupied and produce di-, mono-,
and unglycosylated PrP. A central event associated with TSEs
is the conformational conversion of PrPC into an abnormal,
protease-resistant form, PrPSc (4). During disease, PrPSc is de-
posited in the brain in the form of plaques and ﬁbrils (5).
An extensively studied polymorphism of the human prion gene
is that which results in a methionine-to-valine change at codon
129. The normal frequencies for the three genotypes show wide
variability across populations in different geographical areas (6).
It has been shown that codon 129 genotype may have effects on
susceptibility to disease (7, 8), disease duration (9, 10), pheno-
type of familial forms of CJD (11), neuropathology of sCJD (2),
protease cleavage of PrPSc (12), oligomerization of PrPSc (13),
and PrPSc amyloid formation (14).
Sporadic CJD was originally classiﬁed as a single disease;
however, transmission of 234 sCJD cases to nonhuman primates
demonstrated variability in disease characteristics such as incu-
bation times, duration of illness, and the pathological outcome
(15). More recently sCJD has been classiﬁed into different sub-
groups according to the codon 129 genotype of the host and
proﬁle of PrPSc determined by means of Western blotting (2, 16).
Electrophoresis of the PrPSc protease-resistant core can distin-
guish between two isoforms of the protein commonly referred to
as type 1 (21 kDa) and type 2 (19 kDa), from the mobility of the
unglycosylated component (17). The prion protein codon 129
genotype and the biochemical characteristics of the disease-
associated form (PrPSc) can be combined to form six subgroups
(MM1, MM2, MV1, MV2, VV1, and VV2). Further studies have
been carried out to assess whether disease characteristics, ac-
cording to PrPSc type, are maintained after passage to hosts with
different PRNP genotypes (18, 19).
In vivo transmission studies have been undertaken to identify
sCJD strains. Transmission of sCJD to wild-type mice does not
often result in clinical disease (20); however, transmissions to bank
voles have proved more productive in terms of a clinical outcome,
with sCJD isolates classiﬁed asMM1 andMV1 behaving as a single
strain, but VV2 and MV2 failed to cause disease after inoculation
(21). A number of different lines of transgenic mice have been
produced that express full-length or chimeric human and mouse
PrP genes to facilitate transmission of CJD (22–24). When chal-
lenged with some, but not all, CJD isolates, transgenic mice have
shorter incubation times than wild-type mice, and the data dem-
onstrate that identity between host and agent codon 129 genotype
often, but not always, facilitates transmission.
Previously we reported the use of gene targeting methodology
to produce mice expressing physiological levels of the human
prion protein gene (25). The inserted human PRNP gene is un-
der the direct control of the normal expression modiﬁers for the
equivalent mouse Prnp gene and, after inoculation with human
prions, there will be homologous human PrPSc–PrPC interaction.
These lines have been inbred on a 129Ola background, thus the
only genetic variation (between the different mouse lines) is that
of the codon 129 genotype in the inserted human prion gene.
Thus, the direct effect of an M-to-V substitution in the mature
prion protein can be studied in both the homozygous (HuMM
and HuVV) and heterozygous (HuMV) lines. Six sCJD cases
were selected for transmission to the transgenic mice, each of
which showed the typical characteristics of that subgroup: MM1,
MM2, MV1, MV2, VV1, and VV2. Our aim was to deﬁne the
diversity of sCJD strains and the inﬂuence of codon 129 geno-
type on the transmission properties of sCJD.
Results
Incubation Times on First Passage Indicate Four Strains of sCJD. In-
cubation time data for mice showing clinical TSE symptoms are
shown in Table 1. The presence/absence and time of onset of
clinical manifestation of TSE disease were dependent on both
the PRNP genotype of the host and the inoculum. These data
suggest that there exist four discrete sCJD strains. The ﬁrst strain
comprises the subgroups sCJD(MM1) and sCJD(MV1) that
produced similar incubation times in each of the lines of mice,
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with the shortest in the HuMM and HuMV lines (446–475 d),
whereas incubation times in HuVV mice were more than 100 d
longer. The second strain comprises sCJD(MV2) and sCJD
(VV2) inocula that produced clinical disease with relatively short
incubation times (≈280 d) in the HuVV mice but much longer
incubation times in HuMM and HuMV mice (450–582 d). For
these inoculations, only a few mice in the HuMM and HuMV
lines displayed clinical signs [sCJD(MV2): 3 of 13 HuMM and 2
of 16 HuMV; sCJD(VV2): 4 of 18 HuMM and 1 of 15 HuMV]
compared with the high numbers of HuVV mice displaying
clinical signs [sCJD(MV2): 16 of 17; sCJD(VV2): 13 of 16].
Although the two groups of HuMV mice produced different
incubation periods after inoculation of sCJD(MV2) and sCJD
(VV2), these data were limited to too few mice to compare
statistically. The third and fourth strains comprise sCJD(VV1)
and sCJD(MM2), which had transmission characteristics that
were different from each other and from the other agents. No
clinical disease was observed in the HuMM mice inoculated with
sCJD(VV1), and only two cases were observed in each of the
HuMV and HuVV lines between 546 and 568 d. Sporadic CJD
(MM2) inoculation showed no clinical disease in any of the three
lines of mice.
Vacuolation Proﬁles Demonstrate Strain Diversity of sCJD. Exami-
nation of the vacuolar pathology of sCJD-infected mice allowed
further assessment of the similarities and differences in trans-
mission properties of each inoculum and provided further evi-
dence for four discrete sCJD strains (Table 1). Inoculation with
sCJD(MM1) and sCJD(MV1) produced similar levels of vacu-
olation, with 80–100% of HuMM and HuMV mice and ≈80% of
HuVV mice scored positive for vacuolation. Inoculation with
sCJD(MV2) and sCJD(VV2) produced 100% positive HuVV
mice and ≈33% positive HuMV mice, but there was some vari-
ation in the HuMM mice, with 69% positive with sCJD(MV2)
inoculum compared with 33% with sCJD(VV2). The sCJD
(VV1) inoculum showed no evidence of vacuolation in the
HuMM mice, and ≈50% of mice were positive in the other two
transgenic lines. The sCJD(MM2) inoculum showed no evidence
of TSE vacuolation in any of the three mouse lines. Fig. 1 shows
the lesion proﬁles generated from assessment of TSE vacuola-
tion distribution in the brain. Data for sCJD(MM2) inoculation
(all genotypes) and HuMM mice inoculated with sCJD(VV1)
are absent because no mice were positive for vacuolation. There
were similarities in lesion proﬁles for all genotype mice infected
with both sCJD(MM1) and sCJD(MV1). The distribution of
lesions is characterized by three peaks in the gray matter scores
relating to the superior colliculus (GM3), hippocampus (GM6),
and cingulate and adjacent motor cortex (GM9). Similarities
were also seen between sCJD(MV2) and sCJD(VV2) inocula;
however, unlike sCJD(MM1) and sCJD(MV1), these proﬁles
differed between the mouse lines. The HuMM mice proﬁles had
peak scores for the hippocampus (GM6) and the cingulate and
adjacent motor cortex (GM9) and appeared similar but not id-
entical to those of sCJD(MM1) and sCJD(MV1). The HuVV
mice lesion proﬁles for these two inocula had peaks in the pro-
ﬁles again at GM3, GM6, and GM9; however, region GM9 had
a much higher mean score, and additionally a high score was also
recorded for the cortex region GM8 (retrosplenial and adjacent
motor cortex). The heterozygous HuMV mice inoculated with
sCJD(MV2) and sCJD(VV2) produced lesion proﬁles that were
dissimilar to both homozygous lines of mice and also to the sCJD
(MM1) and sCJD(MV1) inocula. Lesion proﬁles for HuMV and
HuVV mice inoculated with sCJD(VV1) were different from
each other and from all other proﬁles generated.
Detection of PrPSc by Immunocytochemistry. Analysis of PrPSc de-
position was carried out to determine whether distinctive pat-
terns exist for the sCJD subgroups [Fig. 2 (hippocampal/thalamic
targeting), Table 1, and Fig. S1 (cerebellar targeting)]. Brain
sections from all mice in each inoculated group were examined
by immunohistochemistry to assess the speciﬁc targeting of PrPSc
deposition. The degree of within-group variation seemed to de-
pend on the incubation time of the mice, with an increase in
deposition over time. The regions targeted did not change over
this time period.
Both sCJD(MM1)- and sCJD(MV1)-inoculated mice of each
genotype showed similar overall patterns of staining: in the tha-
lamic region with discrete, punctate, deposits; hippocampal tar-
geting of the stratum lacunosum moleculare; and occasional
larger deposits in deep layers of the cerebral cortex. The cere-
bellum was spared with only very little evidence of PrPSc de-
position. The sCJD(MV2)- and sCJD(VV2)-inoculated mice
showed very similar patterns of PrPSc deposition, which were
different from that found with sCJD(MM1) and sCJD(MV1).
The same thalamic regions were targeted as for sCJD(MM1), but
as well as the punctuate deposits, there was an increase in more
diffuse staining. The HuMM and HuMV lines showed a similar
degree of staining concentrated in the ventral posteromedial
and posterolateral thalamic nuclei. For the HuVV line this area
extended to include the lateral dorsal nucleus, the posterior tha-
lamic nuclear group, and the medial dorsal and ventromedial
thalamic nuclei. Outside the thalamic region the HuVV mice
again showed differences from the other lines. The cerebral cortex
was heavily stained with distinctive banding associated with the
cell type layers present. Band 6 showed the densest deposits. In-
tensely stained aggregates were seen in the white matter of the
corpus callosum in both HuMM and HuVV mice and not in the
HuMV mice. The cerebellum showed similar staining patterns,
targeted to the granular layer, for all mouse lines and both in-
ocula. Deposition in the brains of all three genotype mice in-
oculated with sCJD(VV1) showed similar overall patterns of
staining, and this was different from that found for the four sCJD
subgroups discussed above. The deposition was less intense, with
PrPSc detected only in the stratum lacunosum moleculare of the
hippocampus and occasional deposits in the cerebral cortex. The
cerebellum showed no evidence of PrPSc deposition. There was no
evidence of PrPSc deposition in the brains of HuMM mice in-
oculated with sCJD(MM2), which distinguishes this sCJD sub-
group from all of the others. HuMV and HuVV mice showed
a similar pattern of staining, with only very rare small punctate
Table 1. Primary inoculation of sCJD into the three transgenic mouse lines
HuMM HuMV HuVV
sCJD
inoculum IP
Clinical
signs
Vacuolation
present
PrPSc
detected
by ICC IP
Clinical
signs
Vacuolation
present
PrPSc
detected
by ICC IP
Clinical
signs
Vacuolation
present
PrPSc
detected
by ICC
MM1 446 ± 3.1 10/13 13/13 13/13 457 ± 10.5 9/14 14/14 14/14 588 ± 20.9 8/16 13/16 14/16
MV1 446 ± 4.9 15/16 16/16 16/16 475 ± 9.6 15/18 16/18 17/18 603 ± 34.2 7/18 15/18 13/18
MV2 563 ± 2.2 3/13 9/13 10/11 575 ± 37.0 2/16 6/17 15/17 288 ± 3.0 16/17 16/16 15/15
VV2 582 ± 47.8 4/18 6/18 15/17 450 1/15 5/15 12/14 274 ± 3.6 13/16 16/16 15/15
VV1 — 0/16 0/16 2/16 557 ± 11.0 2/14 9/14 1/14 568 ± 0.0 2/14 7/14 7/14
MM2 — 0/16 0/16 0/15 — 0/18 0/18 2/18 — 0/17 0/17 3/17
Primary passage data for incubation period (IP), number of clinical-positive, TSE vacuolation-positive, and immunocytochemistry (ICC)-positive mice, shown out
of group tested. Values are mean ± SEM or number. —, no clinical signs.
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deposits in the thalamic region. The cerebellum showed no evi-
dence of PrPSc deposition. These differences observed with each
subtype conﬁrm evidence of four major sCJD strains: sCJD(MM1
andMV1); sCJD(MV2 and VV2); sCJD(VV1); and sCJD(MM2).
Detection of PrPSc by Western Blot.Western blot detection of PrPSc
was performed on brain material recovered during the postmortem
of each mouse (Fig. S2). The appearance of type 2 PrPSc was re-
stricted to the HuVV mice inoculated with either sCJD(MV2) or
sCJD(VV2) on primary and secondary passage. These mice also
showed a dominance of the diglycosylated form, a Western blot
proﬁle similar to variant CJD (see type 2 standard lanes in Fig. S2).
There was no evidence for the appearance of type 2 PrPSc in mice
homozygous or heterozygous for methionine at codon 129. All of
the other mice/inoculum combinations in which PrPSc has been
detected showed the typical sCJD type 1, monoglycosylated
dominant proﬁle even if the inoculumcontained type 2PrPSc. Very
low levels of PrPSc were seen in the sCJD(VV1) experiment. With
regards to understanding the strain nature of the inocula, the
Western blot data have only limited capacity to conﬁrm the pre-
vious ﬁndings. It is clear that sCJD(MV2) and sCJD(VV2) share
similar properties that are different from the other inocula.
Because all other inoculum/host combinations produce type 1
monoglycosylation dominant PrPSc (where this is present), there
can be no further distinction between those sCJD subgroups.
Secondary Passage in Transgenic Mice. Secondary passage of brain
material from each of the three transgenic mouse lines was set up
for the three commonest subgroups of sCJD (MM1, MV2, and
VV2) to examine the inﬂuence of host PrP in modifying the
strain of agent. Table 2 lists the incubation periods found for the
appearance of clinical TSE signs in the second passage, together
with the scores for mice found with TSE vacuolation. Sporadic
CJD(MM1) showed remarkably close similarities in onset of
clinical TSE signs and number of affected mice between ﬁrst and
second passage regardless of the incubation period or genotype
of the mice that donated the inoculum brain material. For ex-
ample, primary inoculation of HuMM mice produced clinical
disease at a mean time of 446 d, and secondary passage from
HuMM-, HuMV-, and HuVV-sourced inocula gave mean incu-
bation periods of 451, 446, and 451 d, respectively. Additionally,
the extended incubation periods in HuVV mice (≈550 d) were
similar in both primary and all secondary passage experiments.
These data indicate that sCJD(MM1) strain properties are being
propagated efﬁciently and that this can occur independently of
the genotype of the host, even if brain material is sourced from
an HuVV mouse.
Sporadic CJD(MV2) and sCJD(VV2) showed similar primary
passage incubation times, but differences were observed with
these inocula after secondary passage. Incubation times in HuVV
mice were not affected by primary passage–sourced inocula from
either HuMM or HuMV mice and gave incubation periods of
262–288 d. Second passage from HuVV-sourced brains resulted
in reduction of incubation periods to 235–239 d, suggesting that
codon 129 methionine may hinder propagation of this otherwise
efﬁcient genotype/agent combination. Further differences be-
tween primary and secondary passage were restricted to HuMV
and HuMM mice with inocula originating from primary sCJD
(MV2)-infected HuMV mice and sCJD(VV2)-infected HuMM
mice. Reduction in incubation periods (by ≈100 d) and an in-
crease in clinically positive mice compared with primary passage
suggest that the agent may be adapting toward having properties
more similar to sCJD(MM1) and sCJD(MV1).
Fig. 2. Comparison of immunocytochemistry data from transgenic mice
inoculated with six sCJD subgroups. PrPSc deposition within the brain was
assessed for variation in brain region targeted and morphology of deposits,
in the understanding that this may vary according to the sCJD agent strain
inoculated and the host codon 129 genotype. Immunocytochemistry with
anti-PrP antibody (6H4, brown staining) was performed on histological sec-
tions of the mouse brains. Representative sections are shown for coronal
sections through the hippocampus/thalamus from primary passage mice. All
HuMM mice inoculated with sCJD(MM2) were negative for PrPSc deposition.
(Magniﬁcation: 2.5×.)
Fig. 1. Lesion proﬁle charts of primary passage
vacuolation scoring data. The distribution and in-
tensity of TSE-associated vacuolation was assessed
for each mouse in the primary inoculation ex-
periments. Mean vacuolation scores for nine
gray matter (GM1–GM9) and three white matter
(WM1–WM3) brain regions were plotted. Lesion
proﬁle data have been grouped horizontally
according to the predicted sCJD strain groupings
and vertically according to host codon 129 geno-
type. No data are shown for sCJD(VV1) in HuMM
mice and for sCJD(MM2) because no TSE vacuola-
tion was observed. Error bars, ±SEM; mean values
based on at least ﬁve individual mouse scores;
brain regions deﬁned in Materials and Methods.
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The number of mice positive for the presence of TSE-associated
vacuolation closely followed the similarities and differences that
were seen for clinical signs. In addition, the HuMM and HuMV
mice (discussed above) that showed reductions in incubation pe-
riods were >90% positive, unlike 33–50% for primary transmission
(see asterisked data in Table 1 and Table 2). In contrast to the
primary transmission data, these results for incubation period and
the appearance of TSE vacuolation may indicate a divergence of
the strain properties of sCJD(MV2) and sCJD(VV2). Visual com-
parison of the lesion proﬁle data (Fig. 3) showed that with each
genotype host there were many instances in which the second
passage proﬁle was similar to the ﬁrst passage. This was seen even
when passage occurred from an alternative genotype host. For
sCJD(MM1) the lesion proﬁles showed clear uniformity across
all mice lines and with passage from the three genotype primary
inoculations. Second passage data showed a general lowering of
the scores in regions other than those peak scores seen in pri-
mary passage [superior colliculus (GM3), hippocampus (GM6),
and cingulate and adjacent motor cortex (GM9)], suggesting ad-
aptation to a more focused pathological response. This effect was
not seen in the sCJD(MV2) and sCJD(VV2) passage data. Overall,
passage of sCJD(MV2) and sCJD(VV2) gave similar data sets. The
HuVV hosts with passage from each different genotype mice had
proﬁles that most closely mirrored the primary data, whereas al-
though theHuMMvacuolation scores gave a similar overall pattern
there was more variation between the passage experiments. The
HuMV response to the second passage inocula was similar to pri-
mary passage in that the proﬁles were variable and had wide SE
ranges. Scores for the hippocampus (GM6) region in HuMM and
HuMV mice may highlight a potential adaptation of the sCJD
(MV2) and sCJD(VV2) agents, as shown by a more pronounced
peak in the lesion proﬁle at this point.
Sporadic CJD(MM1) seems to have dominance over the ge-
notype of the host, with near identical lesion proﬁle patterns for
all primary and secondary passage mice. The patterns seen for
both sCJD(MV2) and sCJD(VV2) are similar only within the
HuMM and HuVV host mice groups. The heterozygous HuMV
host shows the most variation between primary and secondary
passage, with no speciﬁc pattern apparent. These data conﬁrm
the primary transmission ﬁndings that sCJD(MM1) has strain
properties different from sCJD(MV2) and sCJD(VV2) and that
the latter pair could be grouped together as one strain. Second-
passageWestern blot analysis was undertaken for mice inoculated
with the sCJD(MV2) agent from an HuVV genotype host and
showed that the same PrPSc types occurred in second passage as
was seen in primary passage (Fig. S2); type 1 was seen in the
HuMM and HuMV mice brains and type 2 in the HuVV mice.
Discussion
The similarities and differences that have emerged during this
study indicate that six subgroups of sCJD, deﬁned here by PrPSc
type and PRNP codon 129 genotype, behave as four different
strains of agent. Sporadic CJD(MM1) and sCJD(MV1) isolates
have identical transmission properties for all three genotypes of
mice. The sCJD(MV2) and sCJD(VV2) isolates have very similar
transmission properties, and both the sCJD(MM2) and sCJD
(VV1) strains behave differently from each other and from the
other isolates. To facilitate discussion of this grouping and for
future reference we propose to name these major strains
“M1CJD,” “V2CJD,” “M2CJD,” and “V1CJD,” respectively. Our
Table 2. Secondary passage of sCJD(MM1), sCJD(MV2), and sCJD(VV2) into the three transgenic mouse lines
HuMM HuMV HuVV
Inoculum IP
Clinical
signs
Vacuolation
present IP
Clinical
signs
Vacuolation
present IP
Clinical
signs
Vacuolation
present
MM1 via HuMM 451 ± 9.8 16/18 18/18 433 ± 15.0 10/18 17/17 539 ± 20.7 6/18 16/18
MM1 via HuMV 446 ± 9.2 16/18 18/18 439 ± 9.9 13/18 18/18 563 ± 25.2 6/18 16/18
MM1 via HuVV 451 ± 6.6 16/18 18/18 484 ± 10.8 11/18 15/18 564 ± 24.7 7/18 15/17
MV2 via HuMM 617 ± 0.5 2/18 15/18 >700 0/17 12/17 277 ± 5.1 15/18 18/18
MV2 via HuMV 475 ± 9.9* 15/18* 18/18* 491 ± 3.4* 5/18* 17/18* 288 ± 3.2 16/17 16/17
MV2 via HuVV
(duplicate)
648 ± 10.0 2/11 9/11 >700 0/12 4/12 235 ± 3.0 11/12 12/12
637 ± 98.0 2/12 7/12 553 1/11 6/11 239 ± 2.5 11/11 11/11
VV2 via HuMM 474 ± 12.2* 16/18* 18/18* 531 ± 46.6* 3/18* 17/18* 264 ± 6.7 14/18 18/18
VV2 via HuMV 392 1/18 12/18 587 1/18 7/18 262 ± 2.5 17/18 18/18
VV2 via HuVV 649 ± 22.5 2/17 15/17 >700 0/18 16/18 237 ± 2.9 13/18 17/18
Secondary passage data for incubation period (IP), clinical scoring, and TSE vacuolation scoring, with number of positive mice shown out of group tested. Values
are mean ± SEM or number. >, No clinical signs up to that time point.
*Difference seen compared with primary passage.
Fig. 3. Secondary passage lesion proﬁles. For
secondary passage experiments of sCJD(MM1),
sCJD(MV2), and sCJD(VV2), mean vacuolation
scores were plotted. Data shown (mean ± SEM)
compare proﬁles between sCJD subgroups (hori-
zontal panels) against the three host genotypes
(vertical panels). Each panel includes the primary
passage lesion proﬁle for that data set. Filled
circles, primary passage; open triangles, second
passage from HuMM inocula; open diamonds,
second passage from HuMV inocula; asterisks,
second passage from HuVV inocula.
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studies, based on incubation time, lesion proﬁle, and PrPSc
Western blot proﬁle and deposition in the brain using a panel of
mice, are based on the “gold standard” strain typing of isolates
originally designed using wild-type mice (26). The difference here
is that our transgenic mice carrying the human PRNP gene have
been substituted for the original wild-type panel, but the inbred
nature and gene targeting of these mice ensure that they are
suitable for such a panel, because there is only a single PrP amino
acid difference between each of the lines. Previous sCJD trans-
mission studies have provided additional evidence for sCJD
(MM1) and sCJD(MV1) having similar transmission properties
and some evidence for similarities between sCJD(MV2) and
sCJD(VV2), but insufﬁcient evidence to make a comparison be-
tween sCJD(VV1) and sCJD(MM2) (21, 24, 27). This study is
a complete analysis of all major sCJD subgroups in inbred mouse
models and is thus capable of a true comparison for distinguishing
the codon 129 homozygote and heterozygote response. However,
the present study examines only single cases of sCJD, with the
assumption that transmission characteristics of a single case will
be representative of the particular subgroup. Although typical
cases of each subgroup were carefully selected for this study, there
is phenotypic variation within sCJD subgroups, and it is therefore
essential that the ﬁndings in this study are replicated in additional
cases. Through a grant from the European Union (NeuroPrion:
HUMTRANS) the panel of mice used in this study have been
provided to a number of other groups, and transmission studies
including a signiﬁcant number of additional sCJD cases are un-
derway. This is of particular importance for the sCJD(MM2)
subgroup because our evidence for a unique strain derives partly
from the inefﬁciency in transmission. Inoculum prepared from
this speciﬁc patient has been used in parallel wild-type and
transgenic studies (28) and shows clear evidence of successful
transmission to those mice, conﬁrming that infectivity titer was
unlikely to be implicated in our ﬁndings.
Evidence in support of these four major strains of sCJD has
recently been reported through a very different approach. Using
in vitro assays, Uro-Coste et al. (29) examined the protease
sensitivity and conformational stability of PrPSc found in 41 pa-
tients with sCJD and found groupings identical to those outlined
in this study (i.e., MM1 and MV1; MV2 and VV2; MM2; VV1).
Because this study was based entirely on in vitro analysis of
PrPSc, this suggests that the four strains of agent identiﬁed in our
study have different conformations of PrPSc. What is perhaps
surprising is that only four discrete strains of sCJD have been
identiﬁed. If the prion protein can exist in many different path-
ogenic isoforms in a single host, why then do only four different
strains of sCJD result in humans? Because the assumption is that
each sCJD case arises spontaneously, this would require strong
selection factors to be operating for these four strains and
against others that may be produced.
There are diverse suggestions as to the origin of sCJD, including
proposals that somatic mutations lead to protein misfolding and
disease (30) or that sCJD has arisen through infection from an
animal source, such as atypical BSE (18, 31). Clearly host PRNP
sequence is not the major criteria for separating the four strains,
although it does seem to have some inﬂuence. If differences in
proteinmisfolding are the basis of the origin of these strains then it
remains to be established what inﬂuences this characteristic. The
quasi-species hypothesis put forward by Collinge et al. (32) sug-
gests that a wide range of mammalian PrPSc conformations are
possible but that only a subset are compatible with each individual
PrP primary structure. This theory may explain both the inﬂuence
of the host genotype and the limited range of sCJD strains, but
such a hypothesis predicts a wider range of strains emerging from
heterozygote individuals, which is not apparent in this study. If the
strain of sCJD was directed not by the exact somatic mutation but
by the cell type in which it arose, then this may lead to differential
misfolding of the protein under control of different misfolding
cofactors present in that cell (33), which could explain the limited
strains of agent associated with each genotype of PRNP. Alter-
natively, there may be only a limited number of somatic mutations
that give rise to sCJD disease within the lifetime of the individual,
and the number of strains may therefore be restricted by those
somatic mutations that are capable of causing rapid-onset disease.
It may be that in vitro analysis has not revealed the extent of sCJD
strains, although some analyses have suggested a greater diversity
of strains (16) than predicted by others (17). Further in vivo strain
typing will establish the range of sCJD strains.
Our study evaluated the precise effect host PRNP codon 129
genotype has on deﬁning transmission and propagation of sCJD
strains in the three genotypes 129MM, 129MV, and 129VV.
There were some speciﬁc combinations of host and inoculum
within the dataset that showed similar characteristics across the
experiments, such as the observation that the HuVV genotype
line developed clinical TSE features with most inocula. HuVV
mice also had the shortest incubation periods by more than 100
d, seen for sCJD(MV2) and sCJD(VV2) inocula. These data
predict that for human iatrogenic spread of sCJD as a whole, this
genotype may be the most susceptible or may show shorter
incubation periods. It is of note that there is an increased
prevalence of young (<50 y) VV genotype sCJD cases across
European countries (United Kingdom, Germany, Italy, and
France) (10). The second common characteristic among the data
was that HuMM and HuMV mice had similar levels of clinical
disease, and mean incubation periods, for four of the six inocula
[excluding sCJD(MM2) and sCJD(VV1)]. This suggests that the
methionine allele of PrPC in the heterozygous HuMV mice may
have had a dominant effect over the valine allele PrPC with
regard to the transmission properties. This study identiﬁes two
areas of risk in terms of developing sCJD. The ﬁrst is that the
highest risk of developing CJD after exposure to infection is
from strain M1CJD [sCJD(MM1) or sCJD(MV1)] and that the
VV genotype confers the highest risk of acquiring infection. The
epidemiological ﬁndings in sCJD demonstrate that approximately
80% of patients are diagnosed with “classic CJD” types MM1 and
MV1, which might intriguingly suggest an infectious rather than
genetic origin for the majority of sCJD cases.
PrPSc type has typically been used as a diagnostic indicator of
the strain of agent infecting an individual. This study, however,
clearly demonstrates that the PrPSc type is a result of the in-
teraction between strain and host. Type 2 PrPSc was seen only in
HuVV mice that had short incubation periods, after inoculation
with primary or secondary sources of strain V2CJD [sCJD(MV2)
and sCJD(VV2)], indicating a speciﬁc pathological response
from the valine homozygous mouse host and inocula with valine
allele type 2 PrPSc. All other mice genotype/inoculum combi-
nations produced type 1 PrPSc.
Second passage of sCJD(MM1), sCJD(MV2), and sCJD(VV2)
in the transgenic mice has allowed us to examine the strain–
genotype correlation and to assess the potential risk of transmission
of these agents within the human population. The sCJD(MM1)
strain transmission properties were unaffected by secondary pas-
sage; the strain could propagate within non-MM hosts and could
transmit from non-MM hosts to all genotypes with the same
properties as primary passage. Because of these facts, there may be
difﬁculty in distinguishing sCJD from iatrogenic CJD caused by
infection from sCJD(MM1) or the M1CJD strain. However, these
data also indicate that passage of the commonest form of sCJD
does not cause adaptation to a more highly transmissible form of
human TSE. Conversely, the other two sCJD subgroups analyzed
by secondary passage seemed to undergo modiﬁcation of proper-
ties dependent on the codon 129 genotype of the source and re-
cipient mouse. The sCJD(MV2) strain transmission properties
were unaffected by secondary passage from an HuMM mouse.
Inoculation of HuVV mice with sCJD(MV2) from an HuVV
mouse produced a reduction in incubation period, suggesting ad-
aptation to a strain with more efﬁcient transmission properties. An
overabundance of iCJD cases in VV genotype recipients of con-
taminated human growth hormone in the United Kingdom sup-
ports these data (34), although this is not the case in France (8). A
form of adaptation was also observed for HuMM and HuMVmice
that received sCJD(MV2) inoculum from an HuMV mouse. Re-
duction in incubation periods and an increased number of mice
positive for vacuolation suggest that a more efﬁcient transmitting
strain has been formed. The sCJD(VV2) strain transmission
properties showed a similar response as for sCJD(MV2). Trans-
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mission properties were unaffected by secondary passage from an
HuMV mouse, and inoculation of HuVV mice with sCJD(VV2)
from an HuVV mouse produced a reduction in incubation period.
Strain adaptation was observed for HuMM and HuMV mice that
received inoculum from sCJD(VV2) passaged through an HuMM
mouse. Analysis of incubation periods and lesion proﬁle data sug-
gests that the adaptation seen may be producing a host response
more similar to that seen for sCJD(MM1) transmission. Therefore
if sCJD(MV2) and sCJD(VV2) were to become iatrogenic sources
of human infection, the host response may be indistinguishable
from sCJD(MM1) and more transmissible with respect to further
infection.
The results from this study can be used as a standard against
which atypical or novel forms of human TSE can be compared.
We have identiﬁed four discrete transmission strains, including
M1CJD: sCJD(MM1 and MV1); V2CJD: sCJD(MV2 and VV2);
V1CJD: sCJD(VV1); and M2CJD: sCJD(MM2). We hypothesize
that iatrogenic spread of sCJD will depend on sCJD subgroup
source and host codon 129 genotype and could produce more
transmissible adapted forms of human TSE, highlighting the
continued need for CJD surveillance and iatrogenic transmission
risk evaluation. The sporadic CJD transmission strain character-
ization described in this study will now allow the full range of
sCJD strains to be examined and atypical strains of human TSE to
be readily identiﬁed so that the public health threats from po-
tential new forms of infectious prion disease can be investigated.
Materials and Methods
Groups of 18 mice were inoculated intracerebrally with brain homogenate
prepared from sCJD patients, and from primary inoculation mice for serial
passage. Standard methodologies were used throughout for scoring of
clinical TSE signs, for assessing the distribution of TSE-associated vacuolation
(35), and for detection (immunocytochemistry) and characterization [West-
ern blot (36)] of the disease-associated form of the prion protein. (See
SI Materials and Methods.)
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